- Previous Close
0.0570 - Open
0.0560 - Bid 0.0550 x --
- Ask 0.0570 x --
- Day's Range
0.0550 - 0.0570 - 52 Week Range
0.0210 - 0.0730 - Volume
117,883 - Avg. Volume
56,616 - Market Cap (intraday)
12.163M - Beta (5Y Monthly) 0.81
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date Feb 26, 2025 - Mar 3, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in animals and humans in Australia. The company offers Gastrointestinal ReProgramming, a proprietary formulation to address irritable bowel syndrome. It also provides Detach for the treatment of diarrhea disease in piglets. Anatara Lifesciences Ltd was incorporated in 2010 and is based in Adelaide, Australia.
anataralifesciences.comRecent News: ANR.AX
View MorePerformance Overview: ANR.AX
Trailing total returns as of 1/16/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ANR.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ANR.AX
View MoreValuation Measures
Market Cap
12.16M
Enterprise Value
10.87M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
8.91
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-59.01%
Return on Equity (ttm)
-126.79%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-1.45M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
982.11k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-744.49k